ImmuPharma is a biopharmaceutical company focused on the development of peptide-based therapies, particularly targeting autoimmune diseases and infections. Their lead candidate, P140 (Lupuzor™), is currently in Phase 3 clinical trials for systemic lupus erythematosus (SLE) and is also being evaluated for chronic inflammatory demyelinating polyneuropathy (CIDP). P140 is distinguished as a non-immunosuppressive treatment, which sets it apart from other therapies in development that often come with significant side effects. The company is leveraging its proprietary technology to enhance the pharmacokinetic and pharmacodynamic properties of peptides, aiming to improve their therapeutic applications and safety profiles.

In addition to P140, ImmuPharma is advancing other programs, including BioAMB, a novel treatment for systemic fungal infections that seeks to mitigate the side effects associated with traditional Amphotericin-B formulations. The company is strategically focused on building a robust pipeline of peptide-based therapeutics, with an emphasis on creating partnerships and licensing opportunities to maximize the value of its assets. By concentrating on areas with high unmet medical needs, such as autoimmune and infectious diseases, ImmuPharma aims to deliver innovative solutions that can significantly impact patient care and generate substantial revenue potential.

United Kingdom

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

ImmuPharma

Company Details